Globus Medical to acquire Nevro for $5.85/sh in all-cash deal valued at ~$250M

GLOBUS MEDICAL INC

All-cash transaction at $5.85/share; 27% premium to 90-day VWAP of $4.61.
Total equity value approx. $250M; expected close by late Q2 2025.
Globus Medical expects Nevro acquisition to be accretive to earnings in second year.
Globus reaffirms standalone 2025 net sales guidance $2.66-$2.69B; combined guidance $2.80-$2.90B.
Preliminary 2024 revenue: Globus $2.52B (+60.6% YoY); Nevro $408-$409M.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.